Etude menée chez des patients ayant déjà participé à une étude sur l’atezolizumab, financée par Genentech et/ou F. Hoffmann-La Roche Ltd (IMbrella A)

Drug: Atezolizumab;Drug: Bevacizumab

Gender: All
Maximum age: N/A
Minimum age: N/A

Inclusion Criteria:

Specific criteria for patients who continue treatment as well as safety and survival
follow-up in the extension study (and survival follow up for pattients who roll over from
IMpower133):

- Eligible for continuing or crossing over to atezolizumab-based therapy at the time of
the parent-study closure as per the parent study or eligible for continuing the
comparator agent(s) in a Genentech- or Roche-sponsored study at the time of the
parent-study closure as per the parent study, with no access to commercially available
comparator agent

- First dose of study treatment in the extension study will be received within 7 days of
the treatment interruption window allowed by the parent study

- Continue to benefit from atezolizumab-based study treatment or from the comparator at
the time of parent-study closure as assessed by the investigator

- Negative serum pregnancy test within 7 days prior to start of study treatment in women
of childbearing potential

Specific criteria for patients from the IMpower133 parent study only who do not continue
treatment in the extension study and/or receive commercially available atezolizumab
(Tecentriq) outside this extension study and continue safety and survival follow-up only in
the extension study:

- Discontinuation of atezolizumab-based therapy in the IMpower133 parent study and in
survival follow- up at the time of IMpower133 parent study closure, or eligible for
continuing or crossing over to atezolizumab-based therapy as per the IMpower133 parent
protocol and have access to commercially available atezolizumab (Tecentriq) outside this
extension study at the time of the IMpower133 parent-study closure

Exclusion Criteria:

Specific criteria for patients who continue treatment as well as safety and survival
follow-up in the extension study:

- Meet of any of the study treatment discontinuation criteria specified in the parent
study at the time of enrollment in the extension study

- Study treatment is commercially marketed in the patient's country for the patient
specific disease and is accessible to the patient

- Time between the last dose of treatment received in parent study and first dose in
extension study is longer than the interruption period (? 7 days) allowed in the
parent study

- Treatment with any anti-cancer treatment (other than treatment permitted in the parent
study) during the time between last treatment in the parent study and the first dose
of study treatment in the extension study

- Permanent discontinuation of atezolizumab for any reason during the parent study or
during the time between last treatment in the parent study and the first dose of study
treatment in the extension study (if applicable)

- Any unresolved or irreversible toxicities during the parent study that required
permanent discontinuation of study treatment, in accordance to the parent study or
local prescribing information

- Ongoing SAE(s) that has not resolved to baseline level or Grade less than or equal to
(<=) 1 from the parent study or during the time between last treatment in the parent
study and the first dose of study treatment in the extension study

- Any serious uncontrolled concomitant disease that would contraindicate the use of
study treatment at the time of the extension study or that would place the participant
at high risk for treatment-related complications

- Concurrent participation in any therapeutic clinical trial (other than the parent
study)

Specific criteria for patients who do not continue treatment in the extension study and/or
receive commercially available atezolizumab (Tecentriq) outside this extension study and
continue safety and survival follow-up only in the extension study:

- Discontinuation of comparator in parent study and in survival follow-up at the time of
parent study closure